Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Regulatory News

Date Source Headline
4th Oct 2019 7:00 am RNS Fasenra approved in the US for self-administration
3rd Oct 2019 4:00 pm RNS Director Declaration
1st Oct 2019 3:00 pm RNS Total Voting Rights
1st Oct 2019 7:05 am RNS AstraZeneca divests rights for Losec to Cheplaphar
1st Oct 2019 7:00 am RNS Update on US regulatory review of PT010 in COPD
30th Sep 2019 3:30 pm RNS Lynparza more than doubled the time without
30th Sep 2019 7:00 am RNS Tagrisso is the only 1st-line treatment for EGFR-
30th Sep 2019 7:00 am RNS Lynparza improved the time women lived without
23rd Sep 2019 7:00 am RNS Qtrilmet recommended for approval in EU by CHMP
18th Sep 2019 7:00 am RNS AstraZeneca amends collaboration with Ironwood
9th Sep 2019 8:38 am RNS Imfinzi is first immunotherapy to show both
4th Sep 2019 7:11 am RNS Tagrisso approved in China as a 1st-line treatment
2nd Sep 2019 3:00 pm RNS Total Voting Rights
2nd Sep 2019 7:05 am RNS Brilinta reduced the risk of cardiovascular events
2nd Sep 2019 7:00 am RNS Detailed results from Phase III DAPA-HF trial
29th Aug 2019 7:00 am RNS Anifrolumab Phase III trial meets primary endpoint
28th Aug 2019 7:05 am RNS Fasenra granted US Orphan Drug Designation for
28th Aug 2019 7:00 am RNS Breztri Aerosphere Phase III ETHOS trial met
22nd Aug 2019 7:00 am RNS Roxadustat approved in China for the treatment of
22nd Aug 2019 7:00 am RNS AstraZeneca agrees to buy US FDA Priority Review
21st Aug 2019 7:00 am RNS Update on the Phase III NEPTUNE trial
20th Aug 2019 7:00 am RNS Farxiga met primary endpoint in landmark Phase III
19th Aug 2019 7:00 am RNS Directorate Change
14th Aug 2019 7:00 am RNS Lynparza Phase III PAOLA-1 trial met primary endpo
14th Aug 2019 7:00 am RNS Calquence granted US Breakthrough Therapy Designat
9th Aug 2019 9:28 am RNS Amendment: Tagrisso significantly improves overall
9th Aug 2019 7:00 am RNS Tagrisso significantly improves overall survival
7th Aug 2019 7:00 am RNS Lynparza Phase III PROfound trial in HRR*
5th Aug 2019 7:00 am RNS Forxiga label updated in the EU in type-2 diabetes
1st Aug 2019 3:00 pm RNS Total Voting Rights
25th Jul 2019 7:00 am RNS AZN: H1 2019 Results
15th Jul 2019 7:00 am RNS Update on US regulatory decision for Farxiga
12th Jul 2019 7:00 am RNS Imfinzi granted US Orphan Drug Designation for
1st Jul 2019 3:00 pm RNS Total Voting Rights
1st Jul 2019 7:00 am RNS Forxiga receives positive EU CHMP opinion for
1st Jul 2019 7:00 am RNS Fasenra receives positive EU CHMP opinion for self
27th Jun 2019 7:00 am RNS Imfinzi improves overall survival at interim
19th Jun 2019 7:00 am RNS Breztri Aerosphere (PT010) approved in Japan for
19th Jun 2019 7:00 am RNS Lynparza approved in Japan for 1st-line
19th Jun 2019 7:00 am RNS Bevespi Aerosphere approved by the Japanese
FTSE 100 Latest
Value9,068.58
Change-64.23